WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

DNA Electronics at the Forefront for Launch of UK Government "Life Sciences Blueprint"

Details
Research
17 July 2009
DNA Electronics Ltd, a developer of disposable, real-time gene testing at the point-of-care, has been showcased as an exemplary healthcare technology innovator at the launch of the Government’s Life Sciences Blueprint - a range of initiatives aimed at ensuring the UK remains a world-leading location to build and grow life science and biotechnology companies.
Read more ...

EU project tackles pain relief without the side effects

Details
Research
14 July 2009
The EU-funded SOS (Safety of non-steroidal anti-inflammatory drugs) project is working to provide medical professionals with guidance on the risks (both cardiovascular and gastrointestinal) associated with certain painkillers. Ultimately, the project results should help to better protect patients against these side effects. Non-steroidal anti-inflammatory drugs (NSAIDs) help reduce pain and inflammation, and are commonly given to sufferers of arthritis and other degenerative joint diseases.
Read more ...

Manhattan Research Report Explores Online Adherence Opportunities

Details
Research
24 June 2009
Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases its latest consumer marketing research module, "Online Adherence Programs: Evaluating Manufacturers' Opportunity to Impact Patient Adherence", as part of its Cybercitizen Health™ market research and strategic advisory service.
Read more ...

EU-funded study shows that cannabis can damage DNA

Details
Research
23 June 2009
Researchers in the UK have found evidence that smoking cannabis can damage human DNA in ways that could potentially increase the risk of developing cancer. The findings, published in the journal Chemical Research in Toxicology, are an outcome of the ECNIS (Environmental cancer risk, nutrition and individual susceptibility) Network of Excellence, funded with EUR 11 million under the 'Food Quality and Safety' Thematic area of the Sixth Framework Programme (FP6) to study how diet and hereditary factors can influence environmental cancer risk.
Read more ...

New zebrafish model offers new insights into skin cancer

Details
Research
19 June 2009
Scientists in the UK and Switzerland have identified a signalling pathway, PI3K (phosphoinositide 3-kinase) that shows promise as a target for treating aggressive skin cancer. Their results, based on a study of the see-through zebrafish, are published in the journal Disease Models and Mechanisms.
Read more ...

Sharing the Sights of BioMedical and Pharmaceutical Domains on Demo-DVD

Details
Research
18 June 2009
CAST PHARMACAST PHARMA, a premier European 3D pharmaceutical and biomedical animation production company, is pleased to announce the availability of an advanced Demo-DVD to make its audiovisual material more widely available to the existing and further customers from the biomedical and pharmaceutical domains.
Read more ...

More than Half of Rheumatoid Arthritis Patients Feel their Disease Controls their Lives

Details
Research
12 June 2009
Schering-PloughResults from the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey of more than 500 rheumatoid arthritis (RA) patients throughout Europe and Canada revealed a majority of patients still suffer from pain (79 percent), fatigue (67 percent) and joint stiffness (57 percent) on a regular basis despite current treatment, while more than half (51 percent) of RA patients feel their disease controls their life.
Read more ...

More Pharma News ...

  1. Information Technology Award announced for pharmacy in 2010
  2. Regular aspirin use may do more harm than good, study warns
  3. From Pioneer to the World's Leading Scientific Network
  4. Study sheds light on H1N1 origins
  5. Recognition for inventors in the fight against disease
  6. New technology could lead to safer gene therapy
  7. New online platform to help pharmaceutical companies find, evaluate and manage drug partners
  • Start
  • Prev
  • 286
  • 287
  • 288
  • 289
  • 290
  • 291
  • 292
  • 293
  • 294
  • 295
  • Next
  • End

Business & Industry

  • CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
  • Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
  • BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
  • Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
  • AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

Research & Development

  • A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
  • 'Biohybrid' device could restore function in paralysed limbs
  • Scientists use tardigrade proteins for human health breakthrough
  • DNA treatment could delay paralysis that strikes nearly all patients with ALS
  • Scientists reveal a potential new approach to treating liver cancer
  • Normalizing tumor blood vessels may improve immunotherapy against brain cancer
  • Engineered bacteria find tumors, then alert the authorities

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research
  4. Protein could offer therapeutic target for pancreatic cancer

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.